Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445750 | 0.83 | — | — | |
| SCHEMBL29432703 | 0.83 | — | — | |
| SCHEMBL493020 | 0.79 | CYP1A2 (0.56) | CHRNB2CHRNA4CYP1A2CYP2D6CHRM2 | |
| SCHEMBL10379094 | 0.77 | CHRM2 (0.52) | CHRNB2CHRNA4CYP1A2CYP2D6CHRM2 | |
| Hydrochloric Acid SCHEMBL27794086 | 0.77 | CYP1A2 (0.54) | CHRNB2CHRNA4CYP1A2CYP2D6CHRM2 | |
| SCHEMBL774717 | 0.76 | CHRNB2 (0.52) | CHRNB2CHRNA4CYP1A2CYP2D6CHRM2 | |
| SCHEMBL22520043 | 0.76 | CHRM2 (0.51) | CHRNB2CHRNA4CYP1A2CYP2D6CHRM2 | |
| SCHEMBL12509540 | 0.75 | — | — | |
| SCHEMBL13630753 | 0.75 | CYP1A2 (0.52) | CHRNB2CHRNA4CYP1A2CYP2D6CHRM2 | |
| SCHEMBL18771715 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309733-B2 | Imino derivatives, methods for producing the same and insecticides containing the same | Meji Seika Pharma Co., Ltd. (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20110172433-A1 | NOVEL IMINO DERIVATIVES, METHODS FOR PRODUCING THE SAME AND INSECTICIDES CONTAINING THE SAME | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172433-A1 | NOVEL IMINO DERIVATIVES, METHODS FOR PRODUCING THE SAME AND INSECTICIDES CONTAINING THE SAME | CNOT9, CBR1, CBR3 | CHRNB2 333/4885CHRNA4 49/4885CYP1A2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.